Company |
Location |
Amt. (M) |
Details |
Date |
TOTAL: $396M | ||||
Beigene Ltd. |
Beijing |
$75 |
Beigene completed a financing of more than ¥450M (US$75M), which included initial angel and strategic investors and new investors Hillhouse Capital and Citic Capital Partners, as well as an undisclosed blue chip U.S. public investment fund specializing in life sciences |
11/17/14 |
Benevir Biopharm Inc. |
Rockville, Md. |
ND |
Benevir Biopharm closed a series A round with Pansend LLC |
11/20/14 |
Berlin Cures GmbH |
Munich, Germany |
ND |
Berlin Cures GmbH, a new joint spin-off from the Charité Berlin and the German Heart Institute Berlin, secured undisclosed financing from the Swiss company Minerva Partners AG |
11/7/14 |
Biopharmx Corp. |
Menlo Park, Calif. |
$12 |
Biopharmx secured up to $12M in a series A round led by Korea Investment Partners and including $2M in funding tied to certain milestones |
11/11/14 |
Blueprint Medicine Corp. |
Cambridge, Mass. |
$50 |
Blueprint raised $50M in a series C round led by Partner Fund Management, with participation from Wellington Management Co., RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments and Redmile Group, along with existing shareholders Biotechnology Value Fund, Casdin Capital, Fidelity Biosciences, Nextech Invest and Third Rock |
11/13/14 |
Glionova AB |
Stockholm |
$5.7 |
Glionova raised SEK42M ($5.7M) in a series A round co-led by Healthcap and Novo Seeds A/S |
11/14/14 |
Imago Biosciences Inc. |
San Francisco |
$26.5 |
Imago raised $26.5M in a series A round led by Clarus Ventures LLC, with participation from Frazier Healthcare, Amgen Ventures and Merck Research Labs Venture Fund |
11/3/14 |
Intellia Therapeutics Inc. |
Cambridge, Mass. |
$15 |
Intellia raised $15M in a series A round led by Atlas Venture and Novartis Institutes for Biomedical Research |
11/18/14 |
Karolinska Development AB |
Stockholm |
$8.5 |
Karolinska received an $8.5M investment from CP Group's Chinese subsidiary Sino Biopharmaceutical Ltd. |
11/7/14 |
Liphorus Pharmaceuticals |
Montreal |
ND |
Liphorus Pharmaceuticals was created under an agreement with the Institut de recherches cliniques de Montreal and Sanderling Ventures |
11/7/14 |
N30 Pharmaceuticals Inc. |
Boulder, Colo. |
$30 |
N30 Pharmaceuticals raised $30M in a mezzanine round of financing; new investors included Wellington Management, RA Capital Management, LLC, Jennison Associates LLC, Rock Springs Capital Management LP and Sabby Management LLC, who joined existing investor Deerfield Management Co. LP |
11/20/14 |
Osteoqc |
Montreal |
ND |
Osteoqc closed a seed financing round led by Lumira Capital Investment Management via its Merck Lumira Biosciences Fund |
11/21/14 |
Renova Therapeutics Inc. |
San Diego |
$7.52 |
Renova raised $7.52M through a series C preferred stock financing |
11/19/14 |
Tolero Pharmaceuticals Inc. |
Salt Lake City |
$22.4 |
Tolero closed the second tranche of its series B financing, bringing its total amount raised to $22.4M; Fred Alger Management Inc. led the round, with investments from other institutional and individual investors |
11/7/14 |
Trevi Therapeutics Inc. |
New Haven, Conn. |
$1 |
Trevi disclosed the second and final closing of $11M in a series B financing of $26M led by TPG Biotech and existing angel investors; $25M of the total was accounted for in June |
11/7/14 |
Ziarco Group Ltd. |
Canterbury, UK |
$33.1 |
Ziarco raised $33.1M in a series B round co-led by New Enterprise Associates Inc. and Lundbeckfond Ventures, and joined by Amgen Ventures, BVF Partners LP and Pfizer Venture Investments |
11/11/14 |
Cell Medica Ltd. |
London |
$78 |
Cell Medica raised $78M in a series B round led by Imperial Innovations Group plc, with co-investors Invesco Perpetual and Woodford Investment Management |
11/26/14 |
Promethera Biosciences SA |
Mont-Saint-Guibert, Belgium |
$31.4 |
Promethera completed its series C round to raise €25.33M (US$31.4M) including €20.33M in capital |
11/26/14 |
|
Notes Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. This chart includes only biotech companies that develop therapeutics. ND = Not disclosed. | ||||